B
Brian M. Feldman
Researcher at University of Toronto
Publications - 382
Citations - 21128
Brian M. Feldman is an academic researcher from University of Toronto. The author has contributed to research in topics: Juvenile dermatomyositis & Medicine. The author has an hindex of 70, co-authored 355 publications receiving 16771 citations. Previous affiliations of Brian M. Feldman include Mental Health Research Institute & Hospital for Sick Children.
Papers
More filters
Journal ArticleDOI
Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studies
Ivan Diamond,Robert C. Grant,Brian M. Feldman,Paul B. Pencharz,Simon C. Ling,Aideen M. Moore,Paul W. Wales +6 more
TL;DR: Investigation of how consensus is operationalized in Delphi studies and the role of consensus in determining the results of these studies finds definitions of consensus vary widely and are poorly reported.
Journal ArticleDOI
2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups
Ingrid E. Lundberg,Anna Tjärnlund,Matteo Bottai,Victoria P. Werth,Clarissa Pilkington,Marianne de Visser,Lars Alfredsson,Anthony A. Amato,Richard J. Barohn,Matthew H. Liang,Jasvinder A. Singh,Jasvinder A. Singh,Rohit Aggarwal,Snjolaug Arnardottir,Hector Chinoy,Robert G. Cooper,Katalin Dankó,Mazen M. Dimachkie,Brian M. Feldman,Ignacio García-De La Torre,Patrick Gordon,Taichi Hayashi,James D. Katz,Hitoshi Kohsaka,Peter A. Lachenbruch,Bianca A. Lang,Yuhui Li,Chester V. Oddis,Marzena Olesińska,Ann M. Reed,Lidia Rutkowska-Sak,Helga Sanner,Albert Selva-O'Callaghan,Yeong Wook Song,Jiri Vencovsky,Steven R. Ytterberg,Frederick W. Miller,Frederick W. Miller,Lisa G. Rider,Lisa G. Rider +39 more
TL;DR: New classification criteria for IIM have been endorsed by international rheumatology, dermatology, neurology and paediatric groups, and have been partially validated and generally perform better than existing criteria.
Journal ArticleDOI
WFH Guidelines for the Management of Hemophilia, 3rd edition
Alok Srivastava,Elena Santagostino,Alison Dougall,Steve Kitchen,Megan Sutherland,Steven W. Pipe,Manuel Carcao,Johnny Mahlangu,Margaret V. Ragni,Jerzy Windyga,Adolfo Llinás,Nicholas J. Goddard,Richa Mohan,Pradeep M. Poonnoose,Brian M. Feldman,Sandra Zelman Lewis,H. Marijke van den Berg,Glenn F. Pierce +17 more
TL;DR: The WFH Guidelines for the Management of Hemophilia panelists and co-authors thank the panelists for their time and share their views on how to better understand and treat hemophilia.
Journal ArticleDOI
2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups.
Ingrid E. Lundberg,Anna Tjärnlund,Matteo Bottai,Victoria P. Werth,Clarissa Pilkington,Marianne de Visser,Lars Alfredsson,Anthony A. Amato,Richard J. Barohn,Matthew H. Liang,Jasvinder A. Singh,Rohit Aggarwal,Snjolaug Arnardottir,Hector Chinoy,Robert G. Cooper,Katalin Dankó,Mazen M. Dimachkie,Brian M. Feldman,Ignacio García-De La Torre,Patrick Gordon,Taichi Hayashi,James D. Katz,Hitoshi Kohsaka,Peter A. Lachenbruch,Bianca A. Lang,Yuhui Li,Chester V. Oddis,Marzena Olesińska,Ann M. Reed,Lidia Rutkowska-Sak,Helga Sanner,Albert Selva-O'Callaghan,Yeong Wook Song,Jiri Vencovsky,Steven R. Ytterberg,Frederick W. Miller,Lisa G. Rider,Repository,Ireland +38 more
TL;DR: To develop and validate new classification criteria for adult and juvenile idiopathic inflammatory myopathies (IIM) and their major subgroups.
Journal ArticleDOI
Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis: A Randomized, Placebo-phase Trial
Chester V. Oddis,Ann M. Reed,Rohit Aggarwal,Lisa G. Rider,Dana P. Ascherman,Marc C. Levesque,Richard J. Barohn,Brian M. Feldman,Michael O. Harris-Love,Diane Koontz,Noreen Fertig,Stephanie S. Kelley,Sherrie L. Pryber,Frederick W. Miller,Howard E. Rockette +14 more
TL;DR: Although there were no significant differences in the 2 treatment arms for the primary and secondary end points, 83% of adult and juvenile myositis patients with refractory disease met the DOI, and individual CSMs improved in both groups throughout the 44-week trial.